I
GTBP icon

INVST’s GT Biopharma GTBP Stock Holding History

INVST’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-23,400
Closed -$9.55K – 352
2026
Q1 		$9.55K Buy
+23,400
New +$12.8K ﹤0.01% 335

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

INVST's GTBP Position: Q2 2026 in Review

INVST sold out of GT Biopharma (GTBP) in Q2 2026, closing a stake of 23,400 shares — an estimated $9.55K sold.

INVST first reported a position in GTBP in Q1 2026 and held it in 1 quarter. The position peaked at $9.55K in Q1 2026. 59 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • INVST reported no remaining GT Biopharma position as of Q2 2026 after selling out during the quarter.
  • INVST sold 23,400 GT Biopharma shares in Q2 2026, an estimated $9.55K.
  • INVST first reported a position in GT Biopharma in Q1 2026 and held it in 1 quarter.
  • INVST's GT Biopharma position peaked at $9.55K in Q1 2026.
  • 59 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on INVST's 13F filing for Q2 2026, filed 14 Aug 2026.